Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
Selective cytotoxicity, or the ability to selectively remove certain cell types from a population, is a vital technology that is often applied to various therapeutic applications.
Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies.